SCHEMBL29922276

SCHEMBL29922276

CC(C(=O)N1C(=O)OC[C@H]1Cc1ccccc1)[C@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.49
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
KLK7 P49862 2/20 0.42
KLK5 Q9Y337 1/20 0.42
PPARA Q07869 1/20 0.42
USP30 Q70CQ3 2/20 0.41
STS P08842 1/20 0.41
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
ABHD6 Q9BV23 1/20 0.38
DAGLA Q9Y4D2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25819373 0.95 GPR119 (0.51) GPR119JAK2JAK1KLK7KLK5
SCHEMBL7496058 0.95 GPR119 (0.51) GPR119JAK2JAK1KLK7KLK5
SCHEMBL7497146 0.95 GPR119 (0.51) GPR119JAK2JAK1KLK7KLK5
SCHEMBL28709765 0.90 GPR119 (0.46) GPR119JAK2JAK1KLK7KLK5
SCHEMBL22764724 0.90 GPR119 (0.46) GPR119JAK2JAK1KLK7KLK5
SCHEMBL31346211 0.89 GPR119 (0.45) GPR119JAK2JAK1KLK7KLK5
SCHEMBL31346209 0.89 GPR119 (0.45) GPR119JAK2JAK1KLK7KLK5
SCHEMBL31346203 0.87 GPR119 (0.43) GPR119JAK2JAK1KLK7KLK5
SCHEMBL25957354 0.85 GPR119 (0.42) GPR119JAK2JAK1KLK7KLK5
SCHEMBL31463064 0.84 GPR119 (0.42) GPR119JAK2JAK1KLK7KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230140-A1 NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2025-07-17 US disclosed
CN-117751106-A Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2H-pyranylacetic acid compounds as LPA antagonists 唯久生物技术(苏州)有限公司 2024-03-22 CN disclosed
EP-4330249-A1 NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS Viva Star Biosciences (Suzhou) Co., Ltd. (CN) 2024-03-06 EP disclosed
WO-2022232459-A1 NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230140-A1 NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS LPAR3, LPAR2, LPAR1 GPR119 40/4885JAK2 1245/4885JAK1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.